CLINICAL_TRIALS
ClinicalTrials.gov record update
Molecular Analysis for Therapy Choice (MATCH)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02465060
- Title field or adapter rule
- {'original_value': 'Molecular Analysis for Therapy Choice (MATCH)', 'source_field': 'protocolSection.identificationModule.officialTitle'}
- Ingested At
- 2026-10-31T23:27:21.950412+00:00
- Published At
- 2026-10-26T00:00:00+00:00
- Record Updated At
- 2026-10-26
- Source Retrieved At
- 2026-10-31T22:19:02.163121+00:00
- Timestamp Basis
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
- Date limitation
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-26", "type": "ACTUAL"}- protocolSection.identificationModule.nctId
"NCT02465060"- protocolSection.identificationModule.officialTitle
"Molecular Analysis for Therapy Choice (MATCH)"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct
null
Study condition terms
Interventions recorded in this study
- {'armGroupLabels': ['Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)'], 'description': 'Given PO', 'name': 'Adavosertib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol B (HER2 activating mutation)'], 'description': 'Given PO', 'name': 'Afatinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol B (HER2 activating mutation)'], 'description': 'Given PO', 'name': 'Afatinib Dimaleate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)'], 'description': 'Given PO', 'name': 'Binimetinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol J (HER2 amplification >= 7 copy numbers)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)', 'Subprotocol Z1F (PIK3CA mutation)'], 'description': 'Undergo tumor biopsy', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol J (HER2 amplification >= 7 copy numbers)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)'], 'description': 'Undergo collection of blood samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Y (Akt mutation)'], 'description': 'Given PO', 'name': 'Capivasertib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)', 'Subprotocol Z1F (PIK3CA mutation)'], 'description': 'Undergo computed tomography (CT)', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1F (PIK3CA mutation)', 'Subprotocol Z1G (PTEN loss)', 'Subprotocol Z1H (PTEN mutation)'], 'description': 'Given IV', 'name': 'Copanlisib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1F (PIK3CA mutation)', 'Subprotocol Z1G (PTEN loss)', 'Subprotocol Z1H (PTEN mutation)'], 'description': 'Given IV', 'name': 'Copanlisib Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol F (ALK translocation)', 'Subprotocol G (ROS1 translocation or inversion)'], 'description': 'Given PO', 'name': 'Crizotinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol B (HER2 activating mutation)', 'Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol F (ALK translocation)', 'Subprotocol G (ROS1 translocation or inversion)', 'Subprotocol H (BRAF V600E/R/K/D mutation)', 'Subprotocol I (PIK3CA mutation)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol L (mTOR mutation)', 'Subprotocol M (TSC1 or TSC2 mutation)', 'Subprotocol N (PTEN mutation or deletion and PTEN expression)', 'Subprotocol P (PTEN loss)', 'Subprotocol Q (HER2 amplification)', 'Subprotocol R (BRAF fusion or BRAF non-V600 mutation)', 'Subprotocol S1 (NF1 mutation)', 'Subprotocol S2 (GNAQ or GNA11 mutation)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol U (NF2 inactivating mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol W (FGFR pathway aberrations)', 'Subprotocol X (DDR2 S768R, I638F, or L239R mutation)', 'Subprotocol Y (Akt mutation)', 'Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)', 'Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)', 'Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)', 'Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)', 'Subprotocol Z1F (PIK3CA mutation)', 'Subprotocol Z1G (PTEN loss)', 'Subprotocol Z1H (PTEN mutation)', 'Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)', 'Subprotocol Z1K (AKT mutation)', 'Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)', 'Subprotocol Z1M (LAG-3 expression >= 1%)'], 'description': 'Optional correlative studies', 'name': 'Cytology Specimen Collection Procedure', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol H (BRAF V600E/R/K/D mutation)'], 'description': 'Given PO', 'name': 'Dabrafenib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol H (BRAF V600E/R/K/D mutation)'], 'description': 'Given PO', 'name': 'Dabrafenib Mesylate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol X (DDR2 S768R, I638F, or L239R mutation)'], 'description': 'Given PO', 'name': 'Dasatinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol U (NF2 inactivating mutation)'], 'description': 'Given PO', 'name': 'Defactinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol U (NF2 inactivating mutation)'], 'description': 'Given PO', 'name': 'Defactinib Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol J (HER2 amplification >= 7 copy numbers)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)'], 'description': 'Undergo echocardiography (ECHO)', 'name': 'Echocardiography Test', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)'], 'description': 'Given PO', 'name': 'Erdafitinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol W (FGFR pathway aberrations)'], 'description': 'Given PO', 'name': 'Fexagratinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1K (AKT mutation)'], 'description': 'Given PO', 'name': 'Ipatasertib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol B (HER2 activating mutation)', 'Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol F (ALK translocation)', 'Subprotocol G (ROS1 translocation or inversion)', 'Subprotocol H (BRAF V600E/R/K/D mutation)', 'Subprotocol I (PIK3CA mutation)', 'Subprotocol J (HER2 amplification >= 7 copy numbers)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol L (mTOR mutation)', 'Subprotocol M (TSC1 or TSC2 mutation)', 'Subprotocol N (PTEN mutation or deletion and PTEN expression)', 'Subprotocol P (PTEN loss)', 'Subprotocol Q (HER2 amplification)', 'Subprotocol R (BRAF fusion or BRAF non-V600 mutation)', 'Subprotocol S1 (NF1 mutation)', 'Subprotocol S2 (GNAQ or GNA11 mutation)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol U (NF2 inactivating mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol W (FGFR pathway aberrations)', 'Subprotocol X (DDR2 S768R, I638F, or L239R mutation)', 'Subprotocol Y (Akt mutation)', 'Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)', 'Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)', 'Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)', 'Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)', 'Subprotocol Z1G (PTEN loss)', 'Subprotocol Z1H (PTEN mutation)', 'Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)', 'Subprotocol Z1K (AKT mutation)', 'Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)', 'Subprotocol Z1M (LAG-3 expression >= 1%)'], 'description': 'Undergo molecular analysis', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)'], 'description': 'Given PO', 'name': 'Larotrectinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)'], 'description': 'Given PO', 'name': 'Larotrectinib Sulfate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol K1 (FGFR amplification)', 'Subprotocol K2 (FGFR mutation or fusion)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)', 'Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)', 'Subprotocol Z1F (PIK3CA mutation)'], 'description': 'Undergo magnetic resonance imaging (MRI)', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol E (EGFR T790M or rare activating mutation)'], 'description': 'Undergo MUGA', 'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)', 'Subprotocol Z1M (LAG-3 expression >= 1%)'], 'description': 'Given IV', 'name': 'Nivolumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol E (EGFR T790M or rare activating mutation)'], 'description': 'Given PO', 'name': 'Osimertinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)', 'Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)'], 'description': 'Given PO', 'name': 'Palbociclib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol J (HER2 amplification >= 7 copy numbers)'], 'description': 'Given IV', 'name': 'Pertuzumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol N (PTEN mutation or deletion and PTEN expression)', 'Subprotocol P (PTEN loss)'], 'description': 'Given PO', 'name': 'PI3K-beta Inhibitor GSK2636771', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol C1 (MET amplification)', 'Subprotocol C2 (MET exon 14 deletion/mutation)', 'Subprotocol E (EGFR T790M or rare activating mutation)', 'Subprotocol J (HER2 amplification >= 7 copy numbers)'], 'description': 'Undergo radiologic evaluation', 'name': 'Radiologic Examination', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol A (EGFR activating mutation)', 'Subprotocol T (SMO or PTCH1 mutation)', 'Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)'], 'description': 'Undergo nuclear study', 'name': 'Radionuclide Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1M (LAG-3 expression >= 1%)'], 'description': 'Given IV', 'name': 'Relatlimab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol L (mTOR mutation)', 'Subprotocol M (TSC1 or TSC2 mutation)'], 'description': 'Given PO', 'name': 'Sapanisertib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)'], 'description': 'Given PO', 'name': 'Sunitinib Malate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol I (PIK3CA mutation)'], 'description': 'Given PO', 'name': 'Taselisib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol H (BRAF V600E/R/K/D mutation)', 'Subprotocol R (BRAF fusion or BRAF non-V600 mutation)', 'Subprotocol S1 (NF1 mutation)', 'Subprotocol S2 (GNAQ or GNA11 mutation)'], 'description': 'Given PO', 'name': 'Trametinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol J (HER2 amplification >= 7 copy numbers)', 'Subprotocol Q (HER2 amplification)'], 'description': 'Given IV', 'name': 'Trastuzumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Q (HER2 amplification)'], 'description': 'Given IV', 'name': 'Trastuzumab Emtansine', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)'], 'description': 'Give PO', 'name': 'Ulixertinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Subprotocol T (SMO or PTCH1 mutation)'], 'description': 'Given PO', 'name': 'Vismodegib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
An intervention appearing in a study record does not establish an effect or an approved use.
Drug names recorded in this source
A recorded drug name is not by itself an indication or a condition-specific relationship.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.